Related Experiment Videos
Induction of puberty by prolonged pulsatile LRH administration.
Acta Endocrinologica
|April 1, 1983
Summary
Pulsatile gonadotropin-releasing hormone (GnRH) treatment effectively induces puberty in boys with hypogonadotropic hypogonadism. This therapy accelerates spermatogenesis and demonstrates negative feedback on pituitary hormones.
Area of Science:
- Endocrinology
- Reproductive Medicine
Background:
- Hypogonadotropic hypogonadism (HH) requires hormonal intervention for pubertal induction.
- Pulsatile administration of gonadotropin-releasing hormone (GnRH) is a key therapeutic strategy for HH.
Observation:
- A 17.7-year-old male with HH received pulsatile GnRH treatment over three periods with varying doses and administration routes (intravenous and subcutaneous).
- Treatment resulted in rapid pubertal maturation, including increased penile length, testicular volume, and pubic hair growth.
- Spermatozoa were detected in ejaculate after 21 weeks of treatment.
Findings:
- Pulsatile GnRH, particularly at 2 micrograms per pulse intravenously, effectively induces puberty in males with HH and intact pituitary function.
- Spermatogenesis occurred more rapidly under pulsatile GnRH treatment compared to normal puberty.
- Elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels initially may reflect delayed testicular response, not overdose.
- Testicular hormones demonstrated negative feedback on the pituitary in treated individuals.
Implications:
- Pulsatile GnRH therapy is a viable and effective method for inducing puberty in adolescent males with hypogonadotropic hypogonadism.
- The accelerated timeline for spermatogenesis suggests potential benefits for fertility outcomes.
- Understanding the feedback mechanisms is crucial for optimizing GnRH treatment protocols.